The genomic landscape of pediatric Ewing sarcoma

Cancer Discovery

Volumn 4, Issue 11, 2014, Pages 1326-1341

  Crompton, Brian D ^a   Stewart, Chip ^b   Taylor Weiner, Amaro ^b   Alexe, Gabriela ^a,b,c   Kurek, Kyle C ^d   Calicchio, Monica L ^d   Kiezun, Adam ^b   Carter, Scott L ^b   Shukla, Sachet A ^a   Mehta, Swapnil S ^a   Thorner, Aaron R ^a   de Torres, Carmen ^e   Lavarino, Cinzia ^e   Suñol, Mariona ^e   McKenna, Aaron ^b   Sivachenko, Andrey ^b   Cibulskis, Kristian ^b   Lawrence, Michael S ^b   Stojanov, Petar ^a,b   Rosenberg, Mara ^b   Ambrogio, Lauren ^b   Auclair, Daniel ^b   Seepo, Sara ^b   Blumenstiel, Brendan ^b   DeFelice, Matthew ^b   Imaz Rosshandler, Ivan ^f   Celis, Angela Schwarz Cruzy ^f   Rivera, Miguel N ^b,g   Rodriguez Galindo, Carlos ^a   Fleming, Mark D ^d   Golub, Todd R ^a,b   Getz, Gad ^b,g,h   Mora, Jaume ^e   Stegmaier, Kimberly ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BOSTON UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HOSPITAL SANT JOAN DE DÉU   (Spain)

^f Instituto Nacional de Medicina Genómica   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A7; PROTEIN; PROTEIN P53; STROMAL ANTIGEN 2; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; DNA; STAG2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CELL HETEROGENEITY; CHILD; CHILDHOOD DISEASE; CLONAL EVOLUTION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA EXTRACTION; DNA METHYLATION; EWING SARCOMA; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEXT GENERATION SEQUENCING; PRINCIPAL COMPONENT ANALYSIS; PROTEIN EXPRESSION; RNA EXTRACTION; SOMATIC MUTATION; TRANSCRIPTOME SEQUENCING; WESTERN BLOTTING; WHOLE EXOME SEQUENCING; BONE TUMOR; DNA SEQUENCE; GENE REARRANGEMENT; GENETICS; GENOMICS; METABOLISM; MUTATION; TUMOR CELL LINE;

ANTIGENS, NUCLEAR; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; DNA, NEOPLASM; FEMALE; GENE REARRANGEMENT; GENOMICS; HUMANS; MALE; MUTATION; SARCOMA, EWING; SEQUENCE ANALYSIS, DNA;

EID: 84908447818     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-1037     Document Type: Article

References (73)

1. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012; 122: 2983-8.
2. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481: 329-34.
3. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusionpositive and fusion-negative tumors. Cancer Discov 2014; 4: 216-31.
4. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-74.
5. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-5.
6. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-51.
7. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma. Cancer Cell 2006; 9: 405-16.
8. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
9. Stahl M, Ranft A, Paulussen M, Bolling T, Vieth V, Bielack S, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57: 549-53.
10. Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010; 102: 1272-83.
11. Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, et al. Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children’s Oncology Group. Front Oncol 2013; 3: 141.
12. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15: 2225-32.
13. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23: 548-58.
14. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer-Kuntschik M, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993; 8: 2683-90.
15. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011; 333: 1039-43.
16. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 2014; 10: e1004475.
17. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer 2009; 115: 3526-36.
18. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355-8.
19. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
20. Exome Variant Server NGESPE. Seattle, WA.2014. Available from: http://evs.gs.washington.edu/EVS/. Data retrieved April 2014.
21. Genomes Project C Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65.
22. Huber M, Siegenthaler G, Mirancea N, Marenholz I, Nizetic D, Breitkreutz D, et al. Isolation and characterization of human repetin, a member of the fused gene family of the epidermal differentiation complex. J Invest Dermatol 2005; 124: 998-1007.
23. Kim HS, Maeda N. Structures of two HaeIII-type genes in the human salivary proline-rich protein multigene family. J Biol Chem 1986; 261: 6712-8.
24. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, S erra M, et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing’s sarcoma cells: therapeutic prospects. Int J Cancer 2004; 108: 358-66.
25. Silvany RE, Eliazer S, Wolff NC, Ilaria RL. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 2000; 19: 4523-30.
26. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, et al. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2008; 27: 3282-91.
27. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009; 284: 9074-82.
28. Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS ONE 2009; 4: e7608.
29. Zenali MJ, Zhang PL, Bendel AE, Brown RE. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. Ann Clin Lab Sci 2009; 39: 160-6.
30. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation. Oncogene 2003; 22: 9282-7.
31. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, Ordonez JL, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006; 12: 3532-40.
32. Crompton BD, Carlton AL, Thorner AR, Christie AL, Du J, Calicchio ML, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res 2013; 73: 2873-83.
33. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
34. Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, et al. Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet 2012; 205: 391-404.
35. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013; 45: 1464-9.
36. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013; 45: 1428-30.
37. Evers L, Perez-Mancera PA, Lenkiewicz E, Tang N, Aust D, Knosel T, et al. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med 2014; 6: 9.
38. Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet 2014; 23: 1964-74.
39. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993; 90: 5752-6.
40. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993; 12: 4481-7.
41. Patocs B, Nemeth K, Garami M, Arato G, Kovalszky I, Szendroi M, et al. Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors. Cell Oncol 2013; 36: 191-200.
42. Sgouras DN, Athanasiou MA, Beal GJ, Fisher RJ, Blair DG, Mavrothalassitis GJ. ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. EMBO J 1995; 14: 4781-93.
43. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
44. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
45. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-21.
46. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-93.
47. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45: 970-6.
48. Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell 2013; 152: 1226-36.
49. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-26.
50. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 2011; 25: 2147-57.
51. Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1999; 96: 15103-8.
52. Haering CH, Farcas AM, Arumugam P, Metson J, Nasmyth K. The cohesin ring concatenates sister DNA molecules. Nature 2008; 454: 297-301.
53. Deardorff MA, Wilde JJ, Albrecht M, Dickinson E, Tennstedt S, Braunholz D, et al. RAD21 mutations cause a human cohesinopathy. Am J Hum Genet 2012; 90: 1014-27.
54. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013; 45: 1459-63.
55. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013; 45: 1232-7.
56. Musio A, Selicorni A, Focarelli ML, Gervasini C, Milani D, Russo S, et al. X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations. Nat Genet 2006; 38: 528-30.
57. Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature 2010; 467: 430-5.
58. Yan J, Enge M, Whitington T, Dave K, Liu J, Sur I, et al. Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell 2013; 154: 801-13.
59. Vega H, Waisfisz Q, Gordillo M, Sakai N, Yanagihara I, Yamada M, et al. Roberts syndrome is caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion. Nat Genet 2005; 37: 468-70.
60. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009; 27: 182-9.
61. Levin JZ, Yassour M, Adiconis X, Nusbaum C, Thompson DA, Friedman N, et al. Comprehensive comparative analysis of strandspecific RNA sequencing methods. Nat Methods 2010; 7: 709-15.
62. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
63. Cibulskis K, McKenna A, Fennell T, Banks E, DePristo M, Getz G. ContEst: estimating cross-contamination of human samples in nextgeneration sequencing data. Bioinformatics 2011; 27: 2601-2.
64. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-303.
65. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-9.
66. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-20.
67. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-6.
68. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012; 30: 413-21.
69. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 2012; 22: 1760-74.
70. Costello M, Pugh TJ, Fennell TJ, Stewart C, Lichtenstein L, Meldrim JC, et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res 2013; 41: e67.
71. DeLuca DS, Levin JZ, Sivachenko A, Fennell T, Nazaire MD, Williams C, et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 2012; 28: 1530-2.
72. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621-8.
73. Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2010; 2: a000919.